The big-box electronics retailer reports earnings on Tuesday in a test for its soaring stock.
With the S&P 500 at an all-time high, these four catalysts make miners the only true value left.
The Dogs of the Dow are beating the Dow by 4% so far this year.
Can a regulatory fix ramp up renewables?
With the American Society of Clinical Oncology's annual meeting less than two weeks away, see what drug class could see big gains in the wake of new abstract data.
"Marvel’s Agents of S.H.I.E.L.D." gets the green light.
Google's fast-growing cash hoard is as real as the ground you're standing on. At some point, Google will have to return some to shareholders.
The longer you hold, the better your odds.
Ford is investing big to expand in Russia, and to bring the Russians what they suddenly want most: SUVs.
Being an integrated oil company really paid off for Exxon in this past quarter. Meanwhile, trouble at Chevron’s downstream business meant that it couldn’t bail out the company's earnings in the quarter.
Clinical data and abstracts abound ahead of the American Society of Clinical Oncology's annual meeting.
Uranium prices are up 400% in the last decade -- where are they headed next?
Combining job prospects with average rents, these 10 cities are worth investigating.
Top Google Wallet executive resigns.
As one of the most important conferences in biotechnology approaches (ASCO), we are seeing wild swings of volatility. On Thursday there were several stocks that moved to the downside, and in this piece I am determining if any are a buy after the large moves.
And no, it's not from the folks in Cupertino.
Apple might be wise to follow BlackBerry's lead as it looks to jump-start iPhone sales growth.
One company that's worth paying up for.
Cisco, Microsoft, and JPMorgan led the Dow this week.
Our analysts add two new stocks to their radars.